Does Alnylam Lift All Oligo Boats? The Dicerna IPO
Executive Summary
Dicerna’s debut stood out even in a hot market for biotech IPOs, but it is hard to sort out how much investor enthusiasm was driven by its specific technologies, rub-off from the recent Alnylam/ Sanofi-Genzyme deal, and demands of insiders who wanted liquidity but not dilution.
You may also be interested in...
Dicerna, Flush With Cash, Is Back To The Drawing Board
The RNAi developer is preparing for Phase I clinical trials of three product candidates coming out of a next-generation technology platform. After a decade of RNAi development, CEO Douglas Fambrough says Dicerna is ready to earn back its place as a valuable biotech.
Biopharma Dealmaking Quarterly Statistics, Q1 2014
Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.
Financings Of The Fortnight And The Never-Ending Venture Round
While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.